Newsroom

Celdara Medical Enters into a CRADA with USAMRIID and the Geneva Foundation

Usamriid Thumb

Celdara Medical, a clinical-stage biotechnology company focused on delivering products to patients, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Geneva Foundation, 501(c)3 non-profit organization that advances military medical research.

Continue Reading

Celdara Medical Secures Funding to Provide Seed Grants to Exceptional Early-Stage Biomedical Innovations

Seed Funding

Celdara Medical, LLC and Simbex today announced the award of $250,000 in supplemental funds to the DRIVEN Accelerator Hub. The DRIVEN Accelerator Hub is an NIH-funded consortium led by Celdara Medical (therapeutics and diagnostics) and Simbex (medical devices and digital health) and includes 10 of the leading research institutions in the Northeast. The supplemental funds will be used to create the following programs:

Continue Reading

Celdara Medical Launches New Website for Biomedical Entrepreneurs

Biomedical Entrepreneur Resources

Celdara Medical, LLC today announced the launch of an online resource database for biomedical entrepreneurs: bioentrepreneurresources.com. This database was developed by the DRIVEN Accelerator Hub, an NIH-funded consortium led by Celdara Medical including 10 of the leading research institutions in the Northeast region (NH, VT, ME, DE, and RI). The database is open to biomedical entrepreneurs globally and contains resources from across the country. New resources are added by user submission and curated by DRIVEN.

Continue Reading

Celdara Medical Receives $2.3M SBIR to Advance Treatment for Acute Kidney Injury

Acute Kidney Failure

Celdara Medical, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) fast track award to fund the company’s advancement of APP-103 for the treatment of acute kidney injury (AKI). This project builds on the inventions of co-collaborator Dr. Peter Kang at the Beth Israel Deaconess Medical Center in Boston.

Continue Reading

Enquire now

Give us a call or fill in the form below and we'll contact you. We endeavor to answer all inquiries within 24 hours on business days.